Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Dolutegravir for HIV and Sofosbuvir for Hepatitis C Approved in Europe

The European Commission this week approved 2 important new drugs, ViiV Healthcare's HIV integrase inhibitor dolutegravir (brand name Tivicay) and Gilead Science's nucleotide hepatitis C virus polymerase inhibitor sofosbuvir (Sovaldi).

alt

Read more:

Ribonucleoside Analogs May Be Potential New Class of HIV Drug

A set of compounds known as ribonucleoside analogs -- related to the nucleoside/nucleotide reverse transcriptase inhibitors that currently form the backbone of combination antiretroviral therapy -- demonstrated activity against HIV in laboratory studies, halting viral replication by interrupting HIV DNA production or causing lethal mutations, according to a report in the January 2014 Journal of Virology.

alt

Read more:

HIVandHepatitis.com Complete 2013 Conference Coverage

HIVandHepatitis.com 2013 conference and meeting coverage.

Full conference listing

12/30/13

alt

 

 

Short Antiretroviral Therapy Beneficial during Primary HIV Infection

A short course of combination antiretroviral therapy (ART) started during primary HIV infection is associated with CD4 T-cell gains and viral load reductions after treatment is stopped, according to a meta-analysis published in the December 6 edition of PLoS ONE.

alt

Read more:

Top 13 HIV and Hepatitis Stories of 2013

In our last issue for 2013, HIVandHepatitis.com reviews some the year's major HIV, viral hepatitis, and related news highlights, including the advent of effective new therapies for hepatitis C, new global guidelines recommending earlier HIV treatment, and mixed results in the HIV cure field.

alt

Read more:

Happy New Year from HIVandHepatitis.com

alt

Happy Holidays from HIVandHepatitis.com

alt